Circulating PCSK9 and Risk of Myocardial Infarction

Lars E. Laugsand, MD, PhD; Bjørn O. Åsvold, MD, PhD; Lars J. Vatten, MD, PhD; Imre Janszky, MD, PhD; Carl G. Platou, MD; Annika E. Michelsen, PhD; Jan K. Damås, MD, PhD; Pål Aukrust, MD, PhD; Thor Ueland, PhD

doi:10.1016/j.jacbts.2016.06.007

JACC: Basic to Translational Science (Dec 2016)

Circulating PCSK9 and Risk of Myocardial Infarction

Lars E. Laugsand, MD, PhD,
Bjørn O. Åsvold, MD, PhD,
Lars J. Vatten, MD, PhD,
Imre Janszky, MD, PhD,
Carl G. Platou, MD,
Annika E. Michelsen, PhD,
Jan K. Damås, MD, PhD,
Pål Aukrust, MD, PhD,
Thor Ueland, PhD

Affiliations

Lars E. Laugsand, MD, PhD: Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Bjørn O. Åsvold, MD, PhD: Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Lars J. Vatten, MD, PhD: Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Imre Janszky, MD, PhD: Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Carl G. Platou, MD: Department of Public Health, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway
Annika E. Michelsen, PhD: Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
Jan K. Damås, MD, PhD: Centre of Molecular Inflammation Research, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Pål Aukrust, MD, PhD: Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway
Thor Ueland, PhD: Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway

DOI: https://doi.org/10.1016/j.jacbts.2016.06.007
Journal volume & issue: Vol. 1, no. 7
pp. 568 – 575

Abstract

Read online

The usefulness of circulating proprotein convertase subtilisin-kexin type 9 (PCSK9) as a risk marker of coronary heart disease in the general population remains unclear. In a nested case-control study in Norway, 1,488 incident myocardial infarctions were registered during 11.3 years of follow-up and compared with 3,819 controls. Compared with participants in the lowest quartile of PCSK9, myocardial infarction risk was 47% higher in the highest quartile after adjustment for age and sex. After additional adjustment for low-density lipoprotein cholesterol, the association was strongly attenuated. Thus, circulating PCSK9 does not contribute useful information in the assessment of myocardial infarction risk in the general population beyond the information provided by lipid measurements.

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal

Abstract

Keywords